Comment on: Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial: reply. (1st April 2019) - Sircar, Geetabali; Goswami, Rudra Prosad; Sircar, Dipankar; Ghosh, Alakendu; Ghosh, Parasar